Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARADIGM4TB: Platform Trial for Pulmonary Tuberculosis
NCT06114628Phase 2Recruiting
- Sponsor
- University College London
- Start
- Jan 2024
- Primary completion
- Feb 2027
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 5
01
Overview
A Phase 2 trial of ganfeborole, BTZ-043, quabodepistat, delpazolid in pulmonary tuberculosis (TB), sponsored by University College London. Started Jan 2024; status: recruiting.
02
Drugs
ganfeboroleBTZ-043quabodepistatdelpazolid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06114628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06114628.